Exploring the Science and Practice of GLP-1 Receptor Agonists
freecme000
Published on Feb 9, 2022
VIDEO EMBED ORIGINAL SOURCE - PeerView CME
https://www.youtube.com/watch?v=Eu5v5B0wXzk
Chair, John B. Buse, MD, PhD, discusses type 2 diabetes in this CME activity titled "Exploring the Science and Practice of GLP-1 Receptor Agonists: An Update on Current and Emerging Evidence.†For the full presentation, downloadable infographics, complete CME information, and to apply for credit, please visit us at https://PeerView.com/YYH865. CME credit will be available until October 21, 2020.
Category
Add to
Please Sign In or Create Account to use this feature!
Flag Video
Please Sign In or Create Account to use this feature!
Rate video
Please Sign In or Create Account to use this feature!
Rate video
Please Sign In or Create Account to use this feature!
Up next
Autoplay
Autoplay
Recommended
-
Watch Later
31:29Ian de Boer, MD, MS - GLP-1 Receptor Agonists for Patient with Kidney Disease
40 views 833 days ago -
Watch Later
57:22Renal Denervation for Hypertension: State of the Science in 2021
29 views 864 days ago -
Watch Later
24:30Vasopressin-2 receptor blockers: mechanism of action and clinical utility - Q. Qian
27 views 1302 days ago -
Watch Later
01:04:10Picks of the new European Renal Best Practice Guidelines on Vascular Access
32 views 1325 days ago -
Watch Later
![KDIGO Clinical Practice Guideline on Diabetes Management in CKD]()
29:08KDIGO Clinical Practice Guideline on Diabetes Management in CKD
33 views 1117 days ago -
Watch Later
![Renal Mass and Localized Renal Cancer Evaluation and Management]()
11:00Renal Mass and Localized Renal Cancer Evaluation and Management
41 views 1106 days ago -
Watch Later
![COVID-19 and the kidney. Epidemiology, Mechanisms, and Prediction with Dr. Girish Nadkarni]()
59:54 -
Watch Later
![Renal Masses: Inpatient and Outpatient Evaluations (and Updates in Renal Cell Carcinoma)]()
44:53Renal Masses: Inpatient and Outpatient Evaluations (and Updates in Renal Cell Carcinoma)
30 views 1294 days ago
